Sepsis Market

Market Overview: 

The 7 major sepsis markets reached a value of US$ 438.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 907.3 Million by 2034, exhibiting a growth rate (CAGR) of 6.84% during 2024-2034.

The sepsis market has been comprehensively analyzed in IMARC's new report titled "Sepsis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sepsis refers to a potentially life-threatening condition that occurs when the body's response to infection becomes dysregulated and triggers a systemic inflammatory response. This disease can result in a series of alterations, which damage multiple organ systems, causing them to fail and sometimes even leading to death. The symptoms of the ailment can vary but often include fever, rapid heart rate, shivering, lightheadedness, difficulty breathing, mental confusion, etc. Individuals suffering from sepsis may also experience organ dysfunction, such as decreased urine output and abnormal liver function. In severe cases, this illness can lead to septic shock, characterized by extremely low blood pressure and poor organ perfusion. The diagnosis of this sepsis typically involves a combination of clinical evaluation, laboratory tests, and imaging studies. A healthcare practitioner may perform a complete blood count to assess the levels of white blood cells, red blood cells, and platelets, as well as to measure inflammatory markers, such as C-reactive protein and procalcitonin. Additionally, numerous imaging studies, like X-rays, ultrasounds, computed tomography, etc., might be adopted to identify the source of infection.

The increasing cases of bacterial, viral, and fungal infections, that can trigger chain reactions throughout the body are primarily driving the sepsis market. In addition to this, the expanding geriatric population, who are prone to chronic health conditions and a weakened immune system, is also bolstering the market growth. Furthermore, the widespread adoption of effective drugs, including anti-anxiety medications, antipyretics, anticoagulants, etc., for managing the symptoms of the ailment is acting as another significant growth-inducing factor. Additionally, the inflating utilization of vasopressor support therapy to increase blood pressure and maintain adequate organ perfusion among patients is also augmenting the market growth. Moreover, the escalating demand for central venous catheters, which enable the administration of therapeutic agents directly into the bloodstream, thereby ensuring prompt and targeted treatment, is further creating a positive outlook for the market. Apart from this, the emerging popularity of integrin inhibitors, like cilengitide, on account of their numerous advantages, such as preserving endothelial cell lining and preventing disease progression, is expected to drive the sepsis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the sepsis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for sepsis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the sepsis market in any manner.

Recent Developments:

• In January 2024, Inotrem reported the results of its regulatory contacts with the United States FDA to finalize the design of a single Phase 3 registration trial (ACCURATE) for nangibotide in septic shock. The ACCURATE trial design is based on Phase 2 (ASTONISH) findings that demonstrated nangibotide's high effectiveness and safety profile. The FDA had approved Inotrem's revolutionary biomarker-driven precision medicine approach.
• In November 2023, Inflammatix, Inc. announced the completion of technical development for its TriVerity Acute Infection and Sepsis Test System, which includes the Myrna Instrument, as well as the TriVerity Cartridge. TriVerity is designed to be utilized in emergency department settings in patients with suspected acute infection and sepsis to determine the likelihood of a bacterial infection, a viral infection, and the danger of acute decompensation (requiring ICU-level care).

Key Highlights:

• In the European Union, the annual incidence of sepsis in adults is estimated to be more than 500,000, with over 170,000 progressing to septic shock.
• According to data published in 2020, there were 48.9 million cases and 11 million sepsis-related deaths worldwide, accounting for 20% of total global fatalities.
• Children under the age of five account for nearly half (20 million) of all estimated sepsis cases worldwide.
• An estimated 15 individuals per 1000 hospitalized will get sepsis as a result of receiving health care.
• While sepsis may impact any individual globally, there are considerable regional inequalities in incidence and mortality, with the highest rates in lower-middle-income countries (LMICs).

Drugs:

Giapreza (angiotensin II) was approved by the U.S. FDA as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. Giapreza raises blood pressure by mimicking the body's endogenous angiotensin II regulating peptide, which is essential for the renin-angiotensin-aldosterone system to function. Giapreza is marketed as a 2.5 mg/mL concentrated solution for infusion.

Nangibotide is a TREM-1 inhibitor peptide that has the ability to restore normal inflammatory response, vascular function, and post-septic shock survival. Nangibotide is a formulation of the active component LR12, a chemically synthesized 12-amino acid peptide. LR12 is a selective TREM-1 inhibitor, serving as a decoy receptor and interfering with the binding of TREM-1 to its ligand.

Adrecizumab is a proprietary humanized monoclonal adrenomedullin-specific antibody that is a first-in-class therapeutic for the treatment and prevention of compromised vascular integrity, which is a defining feature of septic shock. Adrecizumab reduced vascular leakage, stabilized circulation by restoring blood pressure, adjusted fluid balance, and decreased vasopressor demand, improved renal function, and reduced septic shock mortality by 50%.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the sepsis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the sepsis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current sepsis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the sepsis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the sepsis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the sepsis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of sepsis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of sepsis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of sepsis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with sepsis across the seven major markets?
• What is the size of the sepsis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of sepsis?
• What will be the growth rate of patients across the seven major markets?
   

Sepsis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for sepsis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the sepsis market?
• What are the key regulatory events related to the sepsis market?
• What is the structure of clinical trial landscape by status related to the sepsis market?
• What is the structure of clinical trial landscape by phase related to the sepsis market?
• What is the structure of clinical trial landscape by route of administration related to the sepsis market?